VitriVax raises $87M Series C to advance Lyme disease vaccine
VitriVax has closed an $87 million Series C, capital that it plans to use to advance its leading Lyme disease vaccine candidate and expand its drug-discovery pipeline.
THIS ARTICLE IS FOR SUBSCRIBERS ONLY
Continue reading for less than $3 per week!
Get a month of award-winning local business news, trends and insights
Access award-winning content today!
Already have a paid subscription?



